Morepen Laboratories Q2 FY25 results (Jul–Sep 2024) and concall

Morepen Labs reported a strong Q2 FY25, demonstrating significant profitability growth despite a modest revenue increase, driven by a strategic shift towards high-value products and export markets. The company is actively expanding its medical devices segment, targeting 40% of total revenue by 2030, and progressing with QIP-funded capacity expansions. Management outlined an ambitious long-term vision for INR 5,000 crores revenue by 2030, supported by margin improvement and new product launches.